scholarly journals Iron Storage Indices: Novel Predictors of Bacteremia in Hemodialysis Patients Initiating Intravenous Iron Therapy

2004 ◽  
Vol 38 (8) ◽  
pp. 1090-1094 ◽  
Author(s):  
Geoffrey S. Teehan ◽  
Dany Bahdouch ◽  
Robin Ruthazer ◽  
Vaidyanathapuram S. Balakrishnan ◽  
David R. Snydman ◽  
...  
Keyword(s):  
Intravenous Iron ◽  
Hemodialysis Patients ◽  
Iron Therapy ◽  
Iron Storage ◽  
Intravenous Iron Therapy

scholarly journals Lycopene supplementation decreases oxidative stress in hemodialysis patients receiving intravenous iron therapy: An open-label, randomized controlled clinical trial

2019 ◽  
Vol 17 ◽  
pp. 205873921882286
Author(s):  
Xiaoyan Xu ◽  
Yu Zheng ◽  
Hanyang Ye ◽  
Lingwei Jin
Keyword(s):  
Oxidative Stress ◽  
Treatment Group ◽  
Oxidant Stress ◽  
Intravenous Iron ◽  
Hemodialysis Patients ◽  
Iron Therapy ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Significant Difference ◽  
Intravenous Iron Therapy

The aim of our study was to evaluate the effect of lycopene on the antioxidant status and the level of homocysteine (HCY) in dialysis patients receiving intravenous iron therapy. A total of 60 hemodialysis patients receiving intravenous iron therapy were randomly assigned to the treatment group and the control group. Patients in the treatment group (n = 30) received oral lycopene and intravenous iron, while patients in the control group (n = 30) only received intravenous iron therapy. At the initiation of the study, oxidant indexes and HCY concentration were tested. After 8 weeks, all of the laboratory variables were repeatedly evaluated. At the initiation of the study, no significant differences were found in the level of oxidant stress and the level of HCY between two groups. After 8 weeks, the levels of superoxide dismutase (SOD) and glutathione peroxidase (GSH-px) decreased, while the levels of malondialdehyde (MDA) and homocystinuria (HCY) increased in both the groups. Besides, the levels of SOD and GSH-px were higher and the level of MDA was lower in the treatment group than in the control group ( P < 0.05, respectively). The level of HCY in the treatment group was relatively low, but there was no significant difference between the two groups. In conclusion, we found that 8-week lycopene supplementation attenuated oxidative stress in hemodialysis patients receiving intravenous iron therapy.

Maintenance intravenous iron therapy in pediatric hemodialysis patients

2001 ◽  
Vol 16 (10) ◽  
pp. 779-783 ◽  
Author(s):  
Henry E. G. Morgan ◽  
Monica Gautam ◽  
D. F. Geary
Keyword(s):  
Intravenous Iron ◽  
Hemodialysis Patients ◽  
Iron Therapy ◽  
Pediatric Hemodialysis ◽  
Intravenous Iron Therapy

scholarly journals Long-Term Prognosis of Hyperferritinemia Induced by Intravenous Iron Therapy in Patients Undergoing Maintenance Hemodialysis: A 10-Year, Single-Center Study

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Sayako Maeda ◽  
Ryo Konishi ◽  
Takuya Morinishi ◽  
Yoko Shimizu ◽  
Haruomi Nishio ◽  
...  
Keyword(s):  
Ferritin Level ◽  
Intravenous Iron ◽  
Hemodialysis Patients ◽  
Iron Therapy ◽  
Maintenance Hemodialysis ◽  
Risk Of Death ◽  
Single Center Study ◽  
Long Term Prognosis ◽  
Intravenous Iron Therapy

Optimal ferritin level in hemodialysis patients between Japan and other countries is controversial. Long-term side effects of iron supplementation in these patients remain unclear. We aimed to elucidate whether past hyperferritinemia in hemodialysis patients was associated with high risk of death and cerebrovascular and cardiovascular diseases (CCVDs). This small retrospective cohort study included approximately 44 patients unintentionally supplemented with excessive intravenous iron. A significantly higher risk of CCVDs was observed in patients with initial serum ferritin levels ≥1000 ng/mL than in the remaining patients. High ferritin levels slowly decreased to <300 ng/mL in a median of 24.2 (10.5–46.5) months without treatment. However, compared with the remaining patients, only patients whose ferritin levels did not decrease to <300 ng/mL steadily had a significantly higher risk of all-cause death (hazard ratio, 9.6). Long-term hyperferritinemia due to intravenous iron therapy is a risk factor for death in maintenance hemodialysis patients. For a prolonged better prognosis, intravenous iron should be carefully administered so as to avoid hyperferritinemia in patients with hemodialysis.

Sign in / Sign up

Export Citation Format

Share Document